Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 3 results.
User Information
Export Records
  1. 1.   A New Generation of Serotype Chimeric Infectivity-Enhanced Conditionally Replicative Adenovirals: The Safety Profile of Ad5/3-Delta 24 in Advance of a Phase I Clinical Trial in Ovarian Cancer Patients
  2. Kim, K. H.; Ryan, M. J.; Estep, J. E.; Miniard, B. M.; Rudge, T. L.; Peggins, J. O.; Broadt, T. L.; Wang, M. H.; Preuss, M. A.; Siegal, G. P.; Hemminki, A.; Harris, R. D.; Aurigemma, R.; Curiel, D. T.; Alvarez, R. D.
  3. Human Gene Therapy. 2011, Jul; 22(7): 821-828.
  1. 2.   A Phase I Study of a Tropism-Modified Conditionally Replicative Adenovirus for Recurrent Malignant Gynecologic Diseases
  2. Kimball, K. J.; Preuss, M. A.; Barnes, M. N.; Wang, M. H.; Siegal, G. P.; Wan, W.; Kuo, H. C.; Saddekni, S.; Stockard, C. R.; Grizzle, W. E.; Harris, R. D.; Aurigemma, R.; Curiel, D. T.; Alvarez, R. D.
  3. Clinical Cancer Research. 2010, Nov; 16(21): 5277-5287.
  1. 3.   Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-Delta 24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer
  2. Page, J. G.; Tian, B. H.; Schweikart, K.; Tomaszewski, J.; Harris, R.; Broadt, T.; Polley-Nelson, J.; Noker, P. E.; Wang, M. H.; Makhija, S.; Aurigemma, R.; Curiel, D. T.; Alvarez, R. D.
  3. American Journal of Obstetrics and Gynecology. 2007, Apr; 196(4):
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel